Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00718861 · ClinicalTrials.gov registry record · Phase 3
3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs
A Phase 3 study of Postmenopausal Osteoporosis, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT00718861: Completed Phase 3 study of Postmenopausal Osteoporosis, sponsored by Novartis Pharmaceuticals.
NCT00718861 is a Phase 3 study of Postmenopausal Osteoporosis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 190 participants, below the 507-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00718861, a Phase 3 study of Postmenopausal Osteoporosis, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
Primary Outcome
Bone Mineral Density (BMD) measured by dual energy x-ray absorptiometry (DXA). DXA consists of two X-ray beams with different energy levels that are aimed at the patient's bones. When soft tissue absorption is subtracted out, the BMD can be determined from the absorption of each beam by bone. Percentage change from Year 6 = 100\*(Year 9 - Year 6)/Year 6.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Zoledronic acid
Study Locations (20)
Buenos Aires
- Novartis Investigative Site - Buenos Aires
- Novartis Investigative Site - Caba
- Novartis Investigative Site - Quilmes
Victoria
- Novartis Investigative Site - Geelong
- Novartis Investigative Site - Parkville
Other
- Novartis Investigative Site - Ghent
- Novartis Investigative Site - Leuven
California
- Novartis Investigative Site - San Diego
Colorado
- Novartis Investigative Site - Lakewood
Georgia
- Novartis Investigative Site - Gainesville
Indiana
- Novartis Investigative Site - Indiamapolis
Maine
- Novartis Investigative Site - Bangor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2008-05 |
| Est. Completion | 2013-04 |
| Phase | Phase 3 |
What the finished NCT00718861 record still lists
NCT00718861 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 507-participant average among 14 other Postmenopausal Osteoporosis trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Postmenopausal Osteoporosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00718861 names 20 study sites across 16 states, led by Buenos Aires, Victoria, Other.
Frequently Asked Questions
What is clinical trial NCT00718861 about?
NCT00718861 is a clinical study titled "3 yr Efficacy & Safety Study of Zoledronic Acid in Post-menopausal Women With Osteoporosis Treated With Zol Acid for 6 Yrs". This second extension will evaluate the efficacy and long term safety of zoledronic acid in women with post-menopausal osteoporosis
What is the current status of trial NCT00718861?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2008-05. Estimated completion is 2013-04.
What conditions does trial NCT00718861 study?
This clinical trial studies the following conditions: Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT00718861?
The interventions under investigation include: Placebo (DRUG), Zoledronic acid (DRUG).
Who is sponsoring clinical trial NCT00718861?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00718861 being conducted?
This trial has 20 study locations across California, Colorado, Georgia, Indiana, Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postmenopausal Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00718861's enrollment target sits among peer trials
190 11th of 14 higher than 4 of 14 other Postmenopausal Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Postmenopausal Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis
COMPLETED · Phase 3
-
A Study of Monthly Risedronate for Osteoporosis
COMPLETED · Phase 3
-
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
COMPLETED · Phase 3
-
Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis
COMPLETED · Phase 3
-
An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women
COMPLETED · Phase 3
-
Dried Plums and Bone Health in Postmenopausal Women
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia